Friday, February 6, 2026

President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients

 On February 5, 2026, President Donald J. Trump announced the launch of TrumpRx.gov, a new initiative aimed at reducing drug prices for American patients. This program offers discounts on many high-cost medicines to align American prices with those in other developed countries.

• Discounts on Medications: TrumpRx.gov will enable patients to access significant discounts on popular and expensive drugs through user-friendly coupons. Initial offerings include medications from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.

• Examples of Price Reductions:

• Ozempic: Monthly price decreases from $1,028 to an average of $350.

• Wegovy: Price drops from $1,349 to as low as $149 for pills, depending on dosage.

• Fertility drugs like Gonal-F will reduce from over $300 to about $168.

• Insulin Lispro will be available for as low as $25 monthly.

• Addressing High Costs: The program aims to provide substantial savings for patients who have been paying high prices for their medications, often exceeding those in other countries.

• Supporting Patients: By offering deep discounts, the initiative is designed to reduce the financial burden on families and ensure that American patients pay fair prices for their medications.

• Executive Actions: This launch follows a series of actions, including an Executive Order from May 2025 and ongoing agreements with pharmaceutical companies to lower prices in the U. S.

President Trump's launch of TrumpRx.gov marks a significant step in addressing high prescription drug prices in the United States. By providing access to lower-cost medicines and promising further price alignments with international standards, the initiative seeks to prioritize American patients' needs and alleviate their financial challenges related to healthcare.

https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/

No comments: